Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Japan
Study Type
Interventional
Intervention
insulin aspart
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- Treated with insulin for at least 12 months and currently on a basal-bolus regimen for at least 12 weeks
- HbA1c below or equal to 11.0%
- BMI (body mass index) below 30 kg/m^2
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Insulin aspart
Arm Description
Outcomes
Primary Outcome Measures
Incidence of hypoglycaemia
Secondary Outcome Measures
Incidence of adverse events (AEs)
Clinical laboratory tests: Haematology and biochemistry
Insulin antibodies
Glycaemic control parameters: Glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01649570
Brief Title
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
Official Title
An Open-labelled, Single-arm, Multi-centre, 6-month Study to Investigate the Safety and Efficacy of NovoRapid as Meal Time Insulin in Type 2 Diabetes Patients Treated on a Basal-bolus Regimen With NPH Human Insulin
Study Type
Interventional
2. Study Status
Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
August 2003 (Actual)
Study Completion Date
August 2003 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
123 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulin aspart
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
insulin aspart
Intervention Description
Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
Primary Outcome Measure Information:
Title
Incidence of hypoglycaemia
Secondary Outcome Measure Information:
Title
Incidence of adverse events (AEs)
Title
Clinical laboratory tests: Haematology and biochemistry
Title
Insulin antibodies
Title
Glycaemic control parameters: Glycosylated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPPG)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
Treated with insulin for at least 12 months and currently on a basal-bolus regimen for at least 12 weeks
HbA1c below or equal to 11.0%
BMI (body mass index) below 30 kg/m^2
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henning Andersen
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
City
Tokyo
ZIP/Postal Code
103
Country
Japan
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Safety and Efficacy of Insulin Aspart in Type 2 Diabetes
We'll reach out to this number within 24 hrs